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ABSTRACT This review aims to concisely chart the
development of two individual research fields, namely
nanomedicines, with specific emphasis on nanoparticles
(NP) and microparticles (MP), and microneedle (MN)
technologies, which have, in the recent past, been
exploited in combinatorial approaches for the efficient
delivery of a variety of medicinal agents across the skin.
This is an emerging and exciting area of pharmaceutical
sciences research within the remit of transdermal drug
delivery and as such will undoubtedly continue to grow
with the emergence of new formulation and fabrication
methodologies for particles and MN. Firstly, the funda-
mental aspects of skin architecture and structure are
outlined, with particular reference to their influence on
NP and MP penetration. Following on from this, a va-
riety of different particles are described, as are the di-
verse range of MN modalities currently under develop-
ment. The review concludes by highlighting some of the
novel delivery systems which have been described in the
literature exploiting these two approaches and directs
the reader towards emerging uses for nanomedicines in
combination with MN.
KEY WORDS drug delivery . microneedles .
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ABBREVIATIONS
API Active pharmaceutical ingredient
BSA Bovine serum albumin
CMC Carboxymethyl cellulose
MN Microneedle
MP Microparticle
NLC Nanostructured lipid carriers
NM Nanomedicines
NP Nanoparticle
OCT Optical coherence tomography
PEG Poly(ethylene glycol)
PLA Poly(lactic acid)
PLGA Poly(d,l-lactic-co-glycolic acid)
PVP Poly(vinylpyrrolidone)
QD Quantum dots
SC Stratum Corneum
SEM Scanning electron microscopy
SLN Solid lipid nanoparticles
INTRODUCTION
The interest on nanotechnology applied to healthcare (also
called nanomedicine) have suffered an exponential growth
during the last 25 years. There are different definitions of
the term Bnanomedicine^ but generally it can be defined as
the use of nanoscale or nanostructured materials in medicine
with unique medical effects related with their structure (1).
Figure 1 shows some examples of different nanomedicines
and their approximate sizes. The applications of
nanomedicine cover treatment, diagnosis, monitoring, and
control of biological systems (2). Consequently, drug delivery
is one of the applications covered by nanomedicine.
Nanoparticles (NPs) have been extensively used to deliver con-
ventional drugs, recombinant proteins, vaccines and nucleo-
tides (3). According to the National Nanotechnology Initiative
(American National Standards Institute), NPs are particles
with all dimensions between 1 and 100 nm (4). However, in
the scientific literature the term Bnanoparticle^ can be found
in a wide variety of works referring to particles larger than
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100 nm. NP formulations show unique size-dependent,
physico-chemical properties and can be made of a wide vari-
ety of compounds such as lipids, sugars, degradable or non-
degradable polymers, metals and organic or inorganic com-
pounds (4). NPs exhibit numerous advantages over traditional
drug delivery systems. Nanoparticulate systems allow
sustained drug release for a prolonged period of time and
additionally provide protection for encapsulated materials
against chemical or proteolytic degradation (4). Besides, they
can be modified with certain ligands in order to target them to
certain parts of the body (5). NPs formulations can be admin-
istered via different routes such as oral, intravenous, pulmo-
nary, nasal and ocular (6). Oral administration continues to be
the preferred route of administration despite the fact that it
presents various drawbacks such as the potential degradation
of the drug in the gastrointestinal tract. Additionally, many
drugs can suffer first-pass effects, resulting in reduction of drug
concentration before it reaches the systemic circulation (7,8).
NPs are promising carriers as they can protect the medicine
from degradation and/or interact with the mucosal surface
and therefore increasing their bioavailability (6,9,10). On the
other hand, parenteral route do not present all the limitations
associated with the gastrointestinal track and allows a quick
onset of action after administration and a reduced dosage of
the drug (11). Also, parenteral route allows the administration
of medicines directly into the bloodstream or into a specific
tissue. This route suffers from poor patient compliance as it is
often associated with pain due to the use of hypodermic
needles. In addition, the use of needles and syringes generates
sharps medical waste thus eliciting the risk of disease transmis-
sion by needle re-use, especially in developing countries (12).
An effective alternative to parenteral and oral delivery systems
is the use of transdermal delivery systems. They are non-
invasive and can be easily self-administered. The primary bar-
rier to transdermal delivery is the stratum corneum (SC), the out-
ermost layer of the skin, a lipophilic barrier that limits the
number of drugs capable of being administered via this route
(13,14). Suitable drugs should be of moderately lowmolecular
weight, have octanol-water partition coefficients that heavily
favour lipids and also exhibit reasonable potency (low dose)
(15–18). To this end, transdermal administration of macro-
molecules, peptides or hydrophilic drugs has, to date,
remained relatively unexploited. Despite all of these limita-
t ions , several medicinal preparat ions have been
commercialised since 1979. In fact, in 1979, the first transder-
mal product was approved for use in the United States.
Currently, the transdermal route vies with oral administration
as the most effective novel research area in active pharmaceu-
tical ingredient (API) delivery. The wealth of the worldwide
transdermal patch market is approaching $32 billion
(American), yet is based on only 20 drugs (19). Therefore a
wide variety of novel systems have been evaluated to try to
enhance the permeability of drugs through the SC (8), includ-
ing the use of NP-based formulations (4,20). Despite all these
promising features however nanoparticulate systems can
achieve only minimal permeation through the SC (20).
A further novel strategy to overcome the SC is the use of
microneedles (MN). MN are minimally invasive devices that
by-pass the SC barrier and thus achieve transdermal drug de-
livery (7,21–23). These devices have garnered much attention
in the pharmaceutical field, particularly over the past decade
due to their ability to facilitate the administration of drugs and
vaccines across the skin but also based on their novel use in the
extraction of biological fluids for monitoring purposes (24,25).
The development and exploitation of combinatorial ap-
proaches to capitalise on the advantages of both NP and
MN delivery systems have increased steadily over the past
15 years. This review aims to comprehensibly chart the devel-
opment of such MN/NP combinatorial applications.
SKIN STRUCTURE AND BARRIER PROPERTIES
WHICH INFLUENCE NANOPARTICLE
AND MICROPARTICLE PENETRATION
The skin is the largest and one of the most complex organs
in the human body and carries out a wide range of functions
(26). This organ contains and protects the internal body
organs and fluids, providing temperature and, to some ex-
tent, humidity control for the body. Moreover, it acts as a
heat, cold, touch and pressure sensor organ connecting with
the central nervous system. As can be seen in Fig. 2, the
multi-layered nature of human skin can be resolved into
three distinct layers: the epidermis, beneath which lies the
much larger dermis and, finally, the deepest layer, the sub-
cutis, also termed the hypodermis (28).
Fig. 1 Structures of different nanomedicines and their approximate sizes. For
comparative purposes, the sizes of biological nanostructures are shown at the
top of the figure. Reproduced with permission from the British Society For
Nanomedicine.
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The outermost layer of the epidermis, and thus the skin, is
the SC. It is now well accepted and documented, that this
layer constitutes the principal barrier for penetration of most
drugs and nanomedicines (NMs) (20,29). The SC typically
has a thickness of 10 μm but factors such as the degree of
hydration and the location of the skin influence it’s thickness.
For instance, the SC on the palms and soles can be between
400 and 600 μm in thickness (29), whilst hydration can lead
to a 4-fold increase in thickness (30). The SCis formed mainly
by 10–25 rows of dead keratinocytes, now called corneocytes,
embedded in the secreted lipids from lamellar bodies (29).
The bricks and mortar model is a common representation of
this layer (30). Corneocytes are polygonal, elongated and flat,
thus resembling ‘bricks’ (18). On the other hand, the ‘mortar’
is formed by a continuous interstitial lipid matrix. These
lipids are arranged in the lamellar phase (alternating layers
of water and lipid bilayers), with some of the lipid bilayers
exhibiting a certain degree of crystallinity (31). The multiple
lipid bilayers residing in the intercellular space are thought to
be responsible for the barrier properties of the SC. These
bilayers prevent desiccation of the underlying tissues by
inhibiting water loss and limit the penetration of substances
from the external environment (31). The SC also has hydro-
philic regions that form aqueous pores facilitating the trans-
epidermal polar route of skin absorption (19). Passive
diffusion is the main mechanism of transport of substances
through this layer. The three acknowledged routes of passive
diffusion are: the transcellular, the intracellular and the
appendageal routes (19). The transcellular route involves dif-
fusion through the lipid matrix occupying the intercellular
spaces of the keratinocytes while the transcellular route in-
volves permeation through the keratinocytes (19). Depending
on the chemical nature of the substance which is diffusing
through the skin, penetration via the intercellular pathway
could involve polar or lipidic routes. Finally, the appendageal
route involves permeation through hair follicles, sebaceous
glands and sweat glands. Typically, the intracellular route
can be used by agents with sizes ranging between 5 and
36 nm while larger molecules (10–210 μm) may penetrate
the skin through the trans-follicular route (20). The mode of
permeation of a NP through the skin cannot be generalised
however as many factors affect NP permeation characteris-
tics. For example, the surface of the skin has an acidic pH
(4.2 to 5.6) that facilitates antimicrobial defence and restricts
inflammation, among other functions (19). This acidic nature
can hinder NP permeation as it can alter the physico-
chemical properties of the particle. One such example are
zinc oxide NPs as acidic pH affects the aggregation and
dissolution kinetics of these particles and consequently affects
its permeability through the skin (32).
Fig. 2 Diagrammatic representation of skin structure. Reproduced with permission from (27).
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In addition to the SC, the viable epidermis is another im-
portant barrier for NP penetration. The epidermis is a strati-
fied epithelium that lies directly above the dermo-epidermal
junction. In contrast to the SC, the epidermis has a hydrophilic
nature that limits the permeation of lipophilic agents. The
presence of proteolytic enzymes that can degrade foreign sub-
stances, in combination with the presence of tight junctions
within the skin layers, limits the permeation of nanomedicines
(NMs) through the viable epidermis (19).
Skin appendages, such as sweat glands and pilosebaceous
units, on the surface of the skin facilitate the penetration of
different agents, including NMs into the skin. Sweat glands are
coiled tubular glands that are extended from the dermis to the
SC (2–5 mm length). Their main functions are thermoregula-
tion and excretion of bodily waste. Pilosebaceous units consist
of hair follicles with one hair (hair infundibulum). These folli-
cles have sebaceous glands associated. Despite the fact that
these units provide large openings on the skin surface, their
density is low and therefore their utility in NP delivery is lim-
ited (19).
CONVENTIONAL NANOPARTICLES
AND MICROPARTICLES FOR TRANSDERMAL
DRUG AND VACCINE DELIVERY
The term Bconventional^ in this article refers to systems based
on passive permeation through the SC, rather than the disrup-
tion of the same. Additionally, the term Bnanoparticle^ will be
used for particles with sizes smaller than 1000 nm.
Transdermal NP delivery has, to date, been used to elicit
local effects (4). Nevertheless, the exact mechanism of NP
penetration remains unclear and there is an ongoing debate
surrounding this mechanism (4,20). The potential skin sites for
targeting NPs are the SC, furrows and hair follicles (Fig. 3) (4).
Thus far, NP-mediated drug delivery into deeper layers of the
skin (epidermis and dermis) without breaching the SC has met
with limited success (4,20,33,34).
Lipidic Vesicles
Liposomes, niosomes®, ethosomes®, transfersomes®,
proliposomes®, pharmacosomes® and vesosomes® are all
different types of lipidic vesicles. All these vehicles normally
present particle sizes larger than 100 nm and a certain degree
of deformability (20). Liposomes are the most popular
nanocarriers (34). They are formed by vesicles that enclose
an aqueous environment by one or multiple lipid bilayers
(mainly phospholipids and/or cholesterol) (35). Niosomes®
were developed to improve the stability of liposomes by in-
cluding non-ionic surfactants in their structure (20).
Ethosomes® are similar to liposomes but can lead to en-
hanced skin penetration due to the fact that they represent a
more elastic, lipidic vesicle (35). Transferosomes® are ultra-
deformable vesicles made of a mixture of phospholipids sup-
plemented with surfactants (35). Proliposomes® are free
flowing particles made of drugs, phospholipids and a water-
soluble porous powder working as a support that increases the
surface of dry lipid (36). Pharmacosomes® are colloidal dis-
persions of drugs covalently linked to phospholipids (36).
Finally, vesosomes® are vesicles inside another vesicle de-
signed mainly for transcutaneous immunization (36).
Transdermal delivery of drugs using these vehicle types has
been extensively studied over the course of the last 35 years.
These nanocarriers have been extensively used for the topical
delivery of anaesthetics (37,38) or anti-inflammatory (39–41)
compounds. Liposomes have been used to deliver antifungal,
antibiotics and a wide variety of peptides to skin tissues by
topical application (36). Furthermore, liposomes have been
shown to have promising properties for the treatment of skin
cancer via the delivery of prodrugs, such as 5 aminolevulinic
acid, for photodynamic therapy or by delivering DNA repair
enzymes to patients with skin cancer (36). Despite these topical
uses, liposomes have little or no value as carriers for transder-
mal drug delivery as these vesicles are not able to cross the SC
(36). In contrast, niosomes®, ethosomes® and transfersomes®
hold more potential in the field of transdermal delivery as they
allow deeper penetration into the skin than conventional
liposomes.
Lipid Nanoparticles
Lipid nanoparticles include solid lipid nanoparticles (SLN)
and nanostructured lipid carriers (NLC). These nanocarriers
Fig. 3 Sites in skin for NP delivery. Topical NP drug delivery takes place in
three major sites: SC surface (a), furrows (b), and openings of hair follicles (c).
TheNPs are depicted in green and the drug in red.Other sites for delivery are
the viable epidermis (e) and dermis (d). Reproduced with permission from
(4).
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were developed to overcome stability problems associat-
ed with liposomes (42). SLN are composed of a single
lipid that is solid at body temperature, coated with a
surfactant acting as stabiliser (43). Conversely, NLC are
formed by a solid lipidic matrix comprising a mixture of
liquid and solid lipids encapsulating a liquid lipidic
nanocompartment (43). SLN and NLC are rigid and
can possess either positive or negative charge, with av-
erage sizes ranging between 50 and 1000 nm (20). SLN
and NLC have been used mainly for cosmetic and der-
matological applications such as the treatment of ecze-
ma and acne (20,42,43).
Worth noting is that fact that the enhanced drug perme-
ation mechanism exhibited by these nanocarriers has been
suggested to be due to the formation of an occlusive film on
the surface of the skin rather than due to the permeation of the
particles through the SC (20).
Polymeric Nanoparticles and Microparticles
The category of polymeric nanoparticles and microparti-
cles may include polymeric micro/nanospheres and mi-
cro/nanocapsules. The former are polymeric particle ma-
trices while the latter are vesicles (generally oily) covered
with polymers. Both types of particles can be produced in
a broad range of sizes possessing either positive or nega-
tive charges (20). These vehicles have been used extensive-
ly as drug delivery systems in a wide variety of different
locations in the body (20). These rigid nanoparticulate
systems do not penetrate the SC but have been shown to
penetrate into hair follicles (20,44–46). Polymeric NPs
have been extensively used as topical delivery systems
(47). Natural polymers (e.g. chitosan, alginate, gelatin
and albumin) have been extensively used to prepare NPs
for topical delivery. Among many natural polymers, chi-
tosan has been frequently utilised in the preparation of
NPs for topical skin delivery (47). It has been used for
the topical delivery of retinol, aciclovir, quercetin, and
even macromolecules such as antisense oligonucleotides
and plasmid DNA (47–49). In addition to NPs made using
natural polymers, there are a wide variety of studies using
synthetic polymers for the preparation of topical NP de-
livery systems. These synthetic polymers can be structured
into two different groups: biodegradables and non-biode-
gradables. Poly(d,l-lactic-co-glycolic acid) (PLGA) is the
most commonly used biodegradable polymer for the prep-
aration of NPs. These NPs have been used for the delivery
of indomethacin, spantide II and ketoprofen, in addition
to other therapeutic agents (50,51). Finally, NPs formulat-
ed with non-degradable polymers, such as polyacrylates,
have also been studied for cutaneous delivery of active
compounds but to a lesser extent (47).
Microemulsions
Microemulsions include formulations composed of stable
emulsions of aqueous and oily phases in the presence of a
surfactant or cosurfactant (52). Droplets formed exhibit high
flexibility with sizes generally less than 150 nm (20).
Microemulsions have been used extensively to enhance the
permeation of drugs (52) and even larger molecules such as
plasmid DNA (53). Intact droplets have not been shown to
penetrate into the skin (20) but rather particles collide with
skin structures and then release their cargos (20).
Microemulsions have been extensively used for cutaneous de-
livery as this nanocarrier displays more pronounced retention
in the skin layers, rather than acting via percutaneous perme-
ation (46). Microemulsions have been used for both cosmetic
(i.e. delivery of ascorbic acid and lycopene) (54,55) and ther-
apeutic applications (46) in the skin. Therapeutic applications
include the delivery of a wide variety of molecules such as
anesthetics, cyclosporine, lidocaine, alpha-tocopherol, temo-
zolomide hexyl ester, ascorbyl palmitate, desmopressin ace-
tate andpaclitaxel (46). Despite their limited efficacy in trans-
dermal delivery however, microemulsions have been used suc-
cessfully for transdermal delivery of several molecules, includ-
ing testosterone, nicotinic acid, lidocaine, estradiol and sodi-
um diclofenac (46).
Metallic and Mineral Nanoparticles
Metallic and mineral nanoparticles include magnetic NPs,
quantum dots (QD), titanium and zinc oxide NPs, carbon
nanotubes and fullerenes. Magnetic NPs are iron derivative
particles with sizes ranging between 2 and 100 nm (20). The
applications of this type of particle include: imaging for the
diagnosis of skin diseases, magnetic assisted drug delivery and
drug targeting, hyperthermia treatment of tumours and mag-
netic transfection of cells (19,20). Baroli et al. demonstrated
that when administered topically, this type of particle was
found to permeate into the deeper layers of the SC, hair folli-
cles, SC-stratum granulosum interface and in some rare cases in
the viable epidermis (56).
QD are core-shell nanomaterials formed by group IV-VI
elements, or group IV elements alone of the periodic table
(57). They have been used extensively for biomedical research
purposes as they possess unique spectral and optoelectronic
properties (57). They are often coated with different surface
coatings, depending on their intended applications. The use of
QD in skin permeation studies have been investigated by var-
ious different research teams (58–62). Despite this however,
there are, to date, no definitive conclusions about the mecha-
nism of permeation of QD through the skin. Several authors
reported QD permeation through porcine skin and murine
skin (60,62) while other authors reported that no conclusive
QD penetration was observed (59,61).Worth noting is the fact
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that none of these publications dealtwith QD permeation
through human skin and as such, all of these findings should
be evaluated carefully before extracting any definitive
conclusions.
T i t an ium and z inc ox ide s a r e examp l e s o f
nanomaterials with the ability to scatter UV light. For this
reason, they are used as an integral component of sun-
screens in the cosmetic industry (19). They are normally
coated with aluminium oxide, silicon dioxide or silicon
oils increasing their sizes and dispersion stabilities (20).
Zinc oxide particle sizes fall between 30 and 200 nm,
while titanium oxide particle sizes can be up to several
microns (19). Nohynek et al. showed that both zinc and
titanium oxide particles penetrate only into the outermost
layers of the SC (63). In contrast however, Kimura et al.
reported that zinc and titanium oxide NPs did not mi-
grate beyond the surface of the skin into the viable epi-
dermis and dermis (64).
Carbon nanotubes and fullerenes are carbon-based
nanomaterials in either the shape of single/multi-
walled hollow tubes or hollow spheres, respectively
(65). Rouse et al. demonstrated the ability of a coupled
fullerene-FITC-peptide compound (3.5 nm) to diffuse
into skin by passive penetration when mechanical stress
was applied to the skin (66). Carbon nanotubes have
been used to enhance transdermal permeation of differ-
ent compounds such as siRNA (67) and indomethacin
(68). Nevertheless, Degim et al. reported that despite
enhancing indomethacin permeation, the selected car-
bon nanotubes were unable to penetrate through the
skin (68).
MICRONEEDLE-MEDIATED TRANSDERMAL
DELIVERY OF NANOPARTICLES
AND MICROPARTICLES
Microneedle Modalities
MN devices are composed of arrays of micron-size needles
(Fig. 4a). The dimensions of these micro-projections generally
range from lengths of only a few micrometres to those as long
as 2000 μm (23).When applied to the skin surface, they bypass
the SC without stimulating dermal nerves due to the short
length of the individual needles (7,21,22). The holes created
in the skin by the MNs can be used to deliver drugs from the
skin surface to the dermal microcirculation (7,21,22).
Therefore, MNs are considered pain-free, minimally invasive
devices that combine the advantages of traditional transder-
mal drug-delivery systems with the targeting of conventional
hypodermic needles (21). Extensive research has been carried
out in the field of MN technology using different materials,
MN designs and fabrication methods (7,21–23,70). In the lit-
erature, five main types of MN design have been described
(23), namely solid, coated, dissolving, hollow and hydrogel-
forming MNs.
Solid MNs are utilised in an approach termed, ‘poke with
patch’ (7,21,22). This strategy involves a two-step process
(Fig. 4b I). In the first step, solid MN arrays are applied to
the skin and subsequently removed. This process creates mi-
cro channels in the skin surface onto which a conventional
drug formulation is applied. Permeation of the active mole-
cules from this formulation occurs via passive diffusion
through the created micro channels. Solid MNs are normally
Fig. 4 Images of a typical silicon MN arrays (a). Scanning electronmicroscopy (SEM) images taken of a typical silicon MN array (a–d) and a digital photograph of a
typical silicon MN array (e). Schematic representation of the main MN modalities (b). Solid MNs (I); coated MNs (II); dissolving MNs (III); hollow MNs (IV) and
hydrogel-forming MNs (V). Reproduced with permission from (69).
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prepared using silicon (71–73), metals or polymers (74). A
wide variety of studies have been published describing the
ability of solidMN arrays to enhance transdermal permeation
of different molecules such as insulin (75), calcein (74,75), nal-
trexone (76) or proteins (75). Additionally, this type of MN
modality has been used in combination with other strategies,
such as iontophoresis, to enhance the efficacy of transdermal
delivery (77).
CoatedMNs consist of a solidMN array (normally made of
silicon or metal) coated with a drug/vaccine formulation
(7,21,22). Coated MNs are applied to the skin and after inser-
tion the coated formulation is deposited into the skin (Fig. 4b
II). This approach is denoted as ‘coat and poke’ (22). Different
strategies can be employed to successfully coat the formula-
tions onto the surface of the MNs (78–80). Coated MNs have
been used to delivery vaccines, proteins, peptides and DNA
into the skin (79,81–84). The use of coated MNs may prove a
viable option for vaccination purposes or for the delivery of
potent drugs but is not suitable for other applications as the
MNs cannot be loaded with large amounts of active molecule.
Dissolving MNs are made of a soluble/biodegradable ma-
trix that includes the active substance. Conventionally,
micromolding techniques are used to produce this type of
MN (7). Following insertion, the needle matrices dissolve/
biodegrade in the skin, thus releasing their cargoes (Fig. 4b
III) (7,21,22). Commonly these types of arrays are made of
sugars, carbohydrates or synthetic polymers (7,23) and have
been utilised to deliver a range of different substances includ-
ing insulin (85,86), low molecular weight heparin (87), ovalbu-
min (88,89), adenovirus vector (89), vaccine antigens (90),
photosensitizers and precursors (73,91), in addition to low
molecular weight drugs (92). Dissolving MNs have also been
used successfully in combination with other permeation en-
hancing strategies such as iontophoresis (93).
Hollow MNs, as the name suggests, consist of hollow
needles that, following insertion, facilitate injection of a fluid
medication into the skin (Fig. 4b IV) (7,21,22). Hollow MNs
allows the delivery of molecules in a continuous fashion. These
devices have been produced using different materials such as
silicon (94), metal (95), hollow glass (96), polymers (97) and
ceramic (98). Hollow MNs have been extensively used to de-
liver insulin (94,96,99).
Finally, hydrogel-forming MN arrays consist of MN made
of a swelling material with a drug reservoir attached to the
baseplate of the array (100–103). After insertion, the array
absorbs interstitial fluid leading to the diffusion of the drug
from the backing through the swollen microprojections into
the skin (Fig. 4b V) (101,102). These MN arrays are produced
mainly using synthetic polymers that can be easily crosslinked
by chemical or physical methods (104). Hydrogel-forming
MN arrays have been employed to deliver a wide range of
different molecules from small molecules (91,101,102,105) to
high molecular weight compounds (101,102,105).
Microneedle-Assisted Nanoparticle/Microparticle
Permeation
Different types of MNs have been used to enhance the per-
meability of NPs and microparticles (MPs). A wide variety of
research studies can be found in the literature dealing with
MN-assisted permeation of nano- and micro-metric particles.
In the first instance, we will describe those studies which main-
ly focused on permeation optimisation of NPs and MPs when
used in combination with MNs. Therapeutic applications of
NPs or MPs used in combination with MNs will be described
in subsequent sections.
The first report of NP permeation through the skin using
MNs was published in 2003 by McAllister et al. (75). In this
work, the ability to enhance permeation of compounds with
different molecular radius (calcein, insulin, BSA and NPs)
using solid MN arrays was evaluated. As a model for NPs,
two types of polystyrene latex nanospheres were employed
(25 and 50 nm of radius). The skin permeability of all the
evaluated compounds, depicted as a function of their molec-
ular radius is presented in Fig. 5 I. Mathematical modelling
was used to predict the permeationmechanism supporting the
idea that transport takes place via diffusion through water-
filled holes in the skin. In a similar way, Coulman et al. studied
the diffusion of fluorescent polystyrene nanospheres (100–
150 nm in diameter) across skin pre-treated with silicon MN
arrays (106). The results of this work are consistent with the
results presented previously by McAllister et al. (75).
Furthermore, in this work, additional factors were studied,
such as surface charge of the particles. The permeation of
the NPs across human epidermal membranes was tested with
variable results, mainly due to the complexities that are asso-
ciated with the use of multi-layered tissue structures (human
epidermal membrane) for MN assisted NP delivery. As can be
seen in Fig. 5 II, NPs were found on the interior surface of the
created microchannels and adsorbed to the corneocyte sur-
faces of the disrupted epidermal membrane. Similar results
were obtained by Zhang et al. using PLGA NPs loaded with
coumarin 6, in combination with solid silicon MN arrays
(107). The two main findings of this work were: (i) following
administration, a larger amount of NP was found in the epi-
dermis rather than in the dermis (Fig. 5 III) and (ii) the per-
meation rate of the NP was dependent on the NP concentra-
tion reaching a limit for higher concentrations (ca. 1.6 mg/
mL). The main results obtained previously by others using
solid MN arrays in combination with NPs/MPs formulations
were corroborated by Gomaa et al. (108). The permeation of
PLGA NPs of differing sizes containing nanoencapsulated
dyes (Rhodamine B and fluorescein isothiocyanate) across ex-
cised porcine skin previously treated with polymeric MN ar-
rays was evaluated. Effect such as the particle size, particle
surface charge, NP composition or chemical nature of the
encapsulated dye strongly influenced the permeation of the
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NPs. Following a different strategy, Zhang et al., in two differ-
ent studies, researched MN-assisted permeation of metallic
MPs into an agarose gel that mimics the skin (109,110).
A different strategy to enhance NP and MP permeation
across the skin is the use of hollow MNs. Following this
approach Wang et al. (96) studied the microinjection of poly-
meric MPs using a single hollow glass MN. The selected MPs
had sizes of 2.5 and 2.8 μm. This work evaluated the ability to
use hollow MNs to inject different compounds intradermally.
The particles were successfully injected into the skin of hairless
rats ex vivo and in vivo. Nevertheless, in order to obtain optimal
delivery, different aspects of the application process should be
tailored and adjusted, such as the injection pressure enlisted or
the retraction of the MN after insertion (Fig. 6a). Similarly
Häfeli et al. developed a syringe-type device equipped with sil-
icon hollow MNs to inject different substances into the skin
(111). They tested this device by injecting an aqueous suspen-
sion containing blue polystyrene microspheres (0.93 μm in di-
ameter) and fluorescent polystyrene microspheres (0.7 μm in
diameter). Using confocal microscopy, the penetration depths
of the microspheres after injection were evaluated elucidating
that the particles can be detected at a depth of 70 μm but the
maximum particle concentration obtained was found to be
approximately 20 μm underneath the surface of the skin
(Fig. 6b). The use of hollow MNs to inject NP is not restricted
to the skin. Ocular drug delivery is a research area that presents
interesting challenges, especially when administering drugs to
the back of the eye. MN arrays in combination with MPs and
NPs can play an interesting role in this niche area. Jiang et al.
demonstrated the ability of hollow, glass MN arrays to inject
NPs and MPs into the sclera in a minimally invasive manner
(113). Poly(lactic acid) (PLA) NPs containing Nile Red were
injected using an insertion-retraction method. The injection of
latex fluorescent MPs required the addition of enzymes to the
tissue to disrupt scleral structure. The same system was used by
Patel et al. to inject NPs (size ranging from 20 to 1000 nm) inside
the suprachoroidal space of the eye (114). The injection of the
particles was optimized illustrating that an increase in infusion
pressure, MN length and intraocular pressure facilitates the
injection process. Furthermore, decreasing NP size promotes
Fig. 5 Skin permeability to molecules and particles of different sizes after treatment with MN arrays (I). The permeability of human cadaver epidermis was
increased by orders of magnitude with a 400-needle array inserted (□) and after the array was removed (•) for calcein, insulin, BSA, and latex nanospheres of
25 nm and 50 nm radius. Predictions are shown for needles inserted (dashed line) and needles removed (solid line) by using a mathematical model. Scanning
electron micrographs of human epidermal membranes treated with a silicon MN device and a subsequent topical application of a fluorescent nanosphere
formulation (II). (a and d), scale bar=50 μm; (b and c), scale bar=10 μm; (e and f), scale bar= 2 μm. Percentage of the applied dose of NPs deposited within
the epidermis and dermis within a 48-h period (III). The skin without MN treatment was used in the control groups. Reproduced with permission from
(75,106,107).
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the injection process. Kim et al. showed recently reported of the
use of hollow MNs to deliver particle-stabilized emulsion drop-
lets to the back of the eye of rabbits in vivo (115). The emulsion
was composed of a high-density perfluorodecalin core (≤35 μm
in diameter) surrounded by fluorescein-tagged polystyrene NPs
(polymeric drug carrier model). After infusion of the emulsion
into the suprachoroidal space of the eye, at least 50% of the
injected NPs were found to be near the macula or ciliary body
depending on the eye cornea orientation.
To a lesser extent, the remaining modalities of MNs have
been used for the delivery of NPs andMPs. Park et al. developed
an alternative method for the production of novel types of MNs
containing different stacked layers in the needle tip and alsoMN
arrays of complex geometries (112).One of the proposed designs
consisted of needle tips made of PLGA (biodegradable polymer)
and a needle shaft composed of poly(ethylene glycol) (PEG)
containing PLGA MPs encapsulating Vitamin B (riboflavin-5′-
phosphate sodium salt dehydrate). This type of MN array was
successfully inserted into human cadaver cornea and post-inser-
tion, the PEG layer dissolved leaving the needles embedded in
the tissue, creating slow drug release reservoirs. Figure 6c shows
a microscopy image of this type of MNs inserted in pig skin.
Different layers can be observed clearly, especially the MPs res-
ervoirs in the epidermis. On the other hand, DeMuth et al. used
PLGA coated MN to deliver plasmid DNA or PLGA NPs into
the viable epidermis (116). This research group showed the po-
tential utility of coated MN for the DNA vaccine delivery and
the possibility of co-delivery of drug loaded in NPs.
Fig. 6 Fluorescence micrographs of histological sections after microinjection of 2.5 μm fluorescent microspheres into hairless rat skin in vivo under pressures
ranging from 2.5 to 20 psi via the same needle and loading for the same time periods (a). Confocal microscopic images of 0.7 μm large fluorescent polystyrene
microspheres at different depths in chicken tissue after injection with a MEMS syringe (b). Multi-layered MN inserted into pig cadaver skin, cryo-sectioned vertically
and viewed by brightfield microscopy (c). Reproduced with permission from (96,111,112).
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Recently, novel nanoneedle technology has been devel-
oped showing potential for delivery of nanomedicines (117).
This technology allows interactions with the intracellular en-
vironment by bypassing cell membranes facilitating the deliv-
ery of drugs and biologics, single-cell stimulation and intracel-
lular sensing (117). Chiappini et al. developed a porous silicon
nanoneedle system for the cytosolic delivery of CdTe QDs
(117). The nanoneedle systemwas successfully used to delivery
QDs to cell cytosol. Furthermore, the same system was tested
for the in vivo superficial intracellular delivery in a mouse an-
imal model. The obtained results suggest that nanoneedle-
mediated delivery is finely-tuned and localized.
Drug Delivery
MN arrays have been using in combination with NP or MP
formulations to deliver many different types of therapeutics
across the skin. The main types of MN arrays used for these
purposes are solid, hollow and dissolving MNs.
The transdermal delivery of insulin using a combination of
MNs and NPs/MPs has been studied by a variety of different
research groups (118–120). Ito et al. developed chondroitin sul-
fate dissolving MNs for the delivery of insulin to mice (118).
Insulin was incorporated into the chondroitin sulfate matrix
adsorbed on two different types of porous MPs (silicon dioxide
and calcium silicate). As a control, MNs containing free insulin
were also prepared. Both types ofMN arrays were employed to
administer insulin to mice and 8 h post-application, blood sam-
ples were collected. In terms of minimum plasma glucose levels,
there were no significant difference across all of the employed
approaches. . Nevertheless, after treatment with the MN-MP-
insulin arrays, a greater hypoglycaemic effect was recorded, in
contrast to that obtained following treatment with MN-insulin
arrays. In addition, MN-MP-insulin systems required longer
times to reach the minimum glucose level. Recently, Yu et al.
developed a Bsmart insulin patch^ formed by MN arrays contain-
ing glucose responsive vesicles loaded with insulin in the tips
(120). These novel vesicles are formed by hypoxia-sensitive
hyaluronic acid conjugated with a hydrophobic component
that can be bio-reduced to hydrophilic under hypoxic condi-
tions (2-nitroimidazole) (Fig. 7a). During enzymatic oxidation of
glucose, a local hypoxic microenviroment is generated. In this
state the reduction of the hyaluronic acid/2-nitromimidazole
conjugate can take place leading to dissociation of the vesicles
and the release of insulin (Fig. 7a and b). The system was eval-
uated in an in vivo mouse model of chemically induced type 1
diabetes showing that use of the arrays was able to control
glucose levels over the course of several hours. In contrast,
Chen et al. studied the use of iontophoresis to enhance the
transdermal delivery of insulin encapsulated in nanovesicles
through holes created in the skin by solid MN arrays (119).
Insulin was encapsulated in nanovesicles prepared using soy-
bean lecithin and propylene glycol. After different pressure ho-
mogenization cycles or ultrasound methodologies, nanovesicles
of different sizes (ranging between 91 and 176 nm), zeta poten-
tials (ranging between −51 and 28 mV) and with insulin en-
trapment efficiencies of up to 89.05%, were obtained.
Iontophoresis alone and combined with MN pre-treatment of
the skin allowed higher insulin permeation than the one obtain-
ed for passive permeation of the vesicles or free insulin. Among
all the different types of nanovesicles that were evaluated, those
with positive zeta potential (zeta potential of +27.8 mV and
107.4 nm in diameter) provided the highest insulin permeation.
This formulation was then evaluated in a mouse model, in
combination with iontophoresis and the reduction in blood
glucose levels was shown to be comparable to that obtained
after subcutaneous injection of insulin.
The treatment of certain cancers, such as those of the oral
cavity, where traditional surgical approaches are not always
feasible, present interesting challenges. One such novel
Fig. 7 Schematic representation of the formation and triggered insulin delivery of the glucose responsive vesicles (a). Schematic of the release from integrated
MN/glucose responsive vesicles patch mechanism of action (b). Reproduced with permission from (120).
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treatment approach involved the use of doxorubicin loaded
PLGA NPs in the treatment of oral cancer (121). In this study,
stainless steel MN arrays were coated with the doxorubicin-NP
formulation for intratumoral drug delivery in a minimally inva-
sive and painless fashion. The particles employed in this work
had an average diameter of 137 nm. MN arrays (700 μm in
length and 200 μm in width) coated with the formulation were
used to deliver doxorubicin into porcine buccal tissue. Confocal
microscopy was used to evaluate the distribution of the NPs
showing that the particles could diffuse to a depth of more than
1mm into the tissue at the insertion point (Fig. 8). In addition to
cancer therapeutics, some antioxidants possess anti-
carcinogenic properties and therefore can be used for cancer
treatment. Paleco et al. developed a system to deliver quercentin
(antioxidant with anti-inflammatory, anti-carcinogenic and
anti-microbial properties) encapsulated in lipidic MPs across
the skin (122). In order to enhance the permeation of the lipidic
MPs, the skin was pre-treated with silicon MN arrays. The MP
formulation was prepared using tristearin as lipidic material
and phosphatidylcholine as surfactant. A topical hydrophilic
cream was then formulated including the quercetin MPs. This
formulation was applied to porcine skin after pre-treatment
with silicon MN arrays (36 MNs over 1 cm2; MNs of height,
200μm) showing a significant increase in the permeation profile
of quercetin, when compared to the administration of free quer-
cetin. In addition to quercetin, the same research group devel-
oped poly(D,L-lactic acid) NPs (sizes 115–150 nm) containing
ketoprofen (123). These nanocarriers were capable of sustained
and controlled drug release over 7 days when tested in vitro.
When the particles were applied onto excised porcine skin after
pre-treatment with silicon MN arrays, the system was able to
release the drug over 24 h.
The use of dyes and pigments as model drugs is a common
practice in pharmaceutical science research. These types of
molecule allow for rapid detection and function as a proof of
concept molecule before beginning to explore the release of
therapeutic drugs. Donnelly et al. studied the use of dissolving
MN arrays as platforms to deliver PLGA NPs containing Nile
Red, a model lipophilic molecule (124). Nile Red was used as a
model of a hydrophobic pre-formed photosensitiser. NP formu-
lation was prepared following a process that combines emulsion
and salting out approaches, yielding particles of approximately
150 nm in diameter. The NPs containing Nile Red were mixed
with poly(methylvinylether/maleic anhydride) and then cast in-
to a mould to form MN arrays. The resulting arrays were
inserted into excised pig skin and the Nile Red permeation
was evaluated using conventional Franz Cell experimentation
apparatus. Control patches that did not contain needles were
also employed as controls. The permeation results demonstrat-
ed that NP permeation was only possible when the NP formu-
lation was applied using dissolving MN arrays. Alternatively,
using the same type of NPs and the same type of MN arrays,
Gomaa et al. showed the ability of this platform to deliver a
different type of dye, Rhodamine B (125). In a similar way
Zhang et al. studied the permeation of PLGA NPs (ca.
160 nm in diameter) in hairless mouse skin pre-treated with
solid MNs. In this instance NPs were loaded with coumarin-6
and R-phycoerythrin (a fluorescent probe) and the particles
diffused through the createdmicroconduits but were not detect-
ed in the receptor compartment. Beyond this, Ke et al. devel-
oped a MN dissolving system containing PLGA MPs loaded
with two dyes (Alexa 488 and Cyanine 5) as model drugs (126).
The peculiarity of these MPs was that they were capable of pH
triggered release. They included NaHCO3 and in contact with
Fig. 8 Delivery of doxorubicin in
porcine buccal tissue after insertion
of MN arrays coated with PLGA
NPs and loaded with doxorobucin.
Confocal fluorescent microscopy
images showing the distribution of
the NPs after insertion of the arrays
in the porcine buccal tissue. The bar
graph shows variation in the mean
fluorescence intensity as a function
of depth from the insertion site.
Scale bar represents: 100 μm.
Reproduced with permission from
(121).
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acidic pH can stimulate the production of CO2 bubbles gener-
ating pores in the PLGA structure. The presence of this porous
in the particle matrix enhanced the release of the dyes mole-
cules. In this study, the resulting poly(vinylpyrrolidone) (PVP)
MN arrays were tested in an in vivo rat model and determined
that this delivery platform was capable of co-delivering two
compounds. In further similar studies, Lee et al. used Nile Red
encapsulated in a nanostructured lipid carrier (ca. 270 nm in
diameter) loaded inside dissolving MN arrays (127). The lipid
nanocarriers were prepared by pressure homogenization and
were mixed with hyaluronic acid to form the MN arrays fol-
lowing a drawing lithography process. The systemwas used in a
Franz Cell diffusion experiment using dorsal skin from a
minipig, thus elucidating the ability of the system to enhance
the permeation of Nile Red to the upper layer of the skin.
In addition to these previously described categories of NPs
and MPs, other interesting vehicles in NM are QD. The use of
QD in combination with MNs have been studied as a promis-
ing drug release system. Justin et al. developed a formulation
containing graphene QD (50–55 nm in diameter and ca.
1.5 nm in height) loaded with lidocaine hydrochloride (128).
The obtained QD were used to prepare a composite in combi-
nation with chitosan that was used to prepare MN arrays.
These arrays showed goodmechanical properties to be inserted
manually inside chicken skin. Additionally the arrays were able
to release in vitro between 50 and 70% of the total amount of
lidocaine loaded. Additionally, the ability to deliver different
molecules from this type of arrays was tested using BSA in
combination with iontophoresis. The prepared MN arrays
showed promising results. Nevertheless the release test was per-
formed placing the array in contact with the release medium
rather than using excised skin or a Franz Cell setup.
Vaccine Delivery
As stated previously, MN arrays have been used in combina-
tion with NP formulations to deliver many different types of
therapeutics across the skin and these have expanded to in-
clude protein antigen and vaccine therapeutics. Succinctly,
successful vaccination is achieved through activation of the
adaptive immune system and induction of long lasting mem-
ory responses. One of the most effective antigen presenting
cell types, dendritic cells (DC), can facilitate robust antigen
specific adaptive immunity. DCs process antigenic fragments,
presenting these to T cells as peptide sequences bound to
MHC (class I and II), resulting in the induction of CD4+
and CD8+ cytotoxic T cells. These activated T cells can act
to modulate infection within the body (129). Professional an-
tigen presenting cells such as DCs and Langerhans cells are
found in vast quantities within the upper layers of the skin
surface. MN technologies facilitate the delivery of therapeutic
agents, including vaccines, to these layers of the skin, through
penetration of the SC layer and deposition of the NP formu-
lation into these immune cell rich skin layers (Fig. 9).
In the recent past, the incorporation of vaccines into
particle-based systems has been proposed as a novel
immunisation strategy for the successful delivery of vaccine
therapeutics (130). The use of particle-based vaccination sys-
tems can aid in the stabilisation of vaccine antigens in vivo, in
addition to providing controlled and sustained release of the
same at the administration site. NPs have been shown, by a
variety of different research groups, to display inherent immu-
nogenic properties. To elaborate, it has been shown that in-
duction of T cell immune responses against encapsulated an-
tigens can be achieved using NP technology, with the NPs
Fig. 9 Schematic representation of
microneedle arrays penetrating the
skin layers releasing nanoparticles,
containing vaccine antigens.
Antigens are processed by dendritic
cells and antigen fragments are
presented to T lymphocytes. T
lymphocytes become active to
CD4+ & CD8+ which then help
to destroy tumour cells and viral
pathogens.
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employed in the studies themselves exhibiting immunogenic
properties, comparable to those of traditional adjuvants such
as aluminium hydroxide and Freund’s complete adjuvant
(131,132). Using NP technology, antigenic material can be
adsorbed or conjugated onto the surface of the particles, or
directly incorporated within the polymeric matrix (133).
Further advantages of the use of antigen/NP formulations
include the fact that such formulations protect labile antigens
from proteolysis, prolong the uptake of antigenic material by
APCs and reduce the release of antigen into systemic circula-
tion (134).
With reference to the use of NP formulations specifically in
conjunction with MN devices, Bal et al. demonstrated the ef-
fective delivery and immunogenicity of N-trimethyl chitosan
(TMC) adjuvanted diphtheria toxoid (DT) in 2010 [7]. These
DT-loaded TMC NPs were coated onto solid metallic MN
arrays, ultimately facilitating their delivery to the skin layers.
TMC has a permanent positive charge and is therefore solu-
ble in water over a wide pH range allowed the researchers to
efficiently create DT loaded NPs. This paper served as an
interesting early example of NP, vaccine and MN combina-
torial approaches, suggesting that NPs could act as a depot for
vaccine antigens which could be delivered across the skin
using a novel MN device (135).
Ovalbumin (OVA) is a widely utilised model antigen in
vaccine delivery studies. In one 2011 study, liquid formula-
tions of OVA or OVA conjugated NPs were applied to the
skin surface in conjunction with roller microneedling devices,
serving as a means of enhancing transdermal delivery. Again,
TMC NPs were employed in this mouse study. In this study,
significantly higher anti-OVA IgG titres were recorded in
those mice which had been treated with OVA conjugated
NPs, in comparison to those which had been treated with free
OVA solution (136). The authors conceded that this demon-
strated that incorporation of protein antigens into NPs can
serve to increase their immunogenicity.
It is worth acknowledging however that the formulation of
any protein antigen into any NP system will not necessarily
result in an immunological response such as those document-
ed previously. Many factors including physical, chemical, and
immunological properties of both antigen and NP may be
responsible for the ultimate success or failure of a particular
formulation. It has been suggested that the optimal vaccine
formulation differs for each administration site, with diffusion
of antigen into the skin potentially the most important rate-
limiting step (135,136).
Although protein based antigens have been the mainstays
of vaccination methodologies for many years, novel DNA
vaccines have and continue to garner significant attention in
the scientific literature. To this end, expanding the remit of
NP formulations to incorporate DNA vaccines for transder-
mal delivery is a logical next step forward in the field. For
example, Kumar et al., presented work on plasmid DNA
coated cationic PLGA NPs. Once again, a solid MN roller
device was used in conjunction the NP formulation but the
NPs were coated with plasmid DNA. This unique means of
DNA vaccine delivery resulted in the successful immunisation
of mice with a gene encoding a protective antigen against
anthrax. An interesting outcome of this study was the fact that
it highlighted how positively charged plasmid DNA coated
NPs elicited a stronger immune response in mice than nega-
tively charged plasmid DNA coated NPs or plasmid DNA
alone (137). In contrast to studies using NP decorated with
plasmid DNA, DNA can also be nanoencapsulated into the
NPs. In one such recent study, McCaffrey et al., illustrated the
inherent potential of a nanoencapsulated plasmid DNA vac-
cine to generate detectable levels of reporter gene expression
in vivo, when delivered from a novel dissolving MN platform
(138). This study was particularly innovative as the NPs were
composed of a self-assembling amphipathic peptide, RALA
(139,140), which facilitates the intracellular delivery of the
DNA across the cell membrane, aids endosomal escape of
the DNA cargo and promotes nuclear localisation of the
DNA for transcription (138–140). This work perfectly exem-
plifies how the combination of two such delivery platforms can
yield the development of a truly state of the art technology
platform for the delivery of, in this instance, nucleic acids.
In 2013, Demuth et al. employed dissolving MN technolo-
gies and NP formulations in a research strategy to study the
rapid implantation of controlled-release polymer depots into
the cutaneous tissue. A rapidly water soluble polyacrylic acid
(PAA) supporting matrix was prepared with needle tips com-
posed of either PLGA NPs or solid PLGA. Upon insertion
into skin, the PAA binder rapidly disintegrated, releasing the
OVA cargo within 5 min. The PLGANP continued to release
subunit vaccine for a number of weeks (141). Sustained release
of vaccine component, localized within the skin layers presents
an opportunity for APC targeting and stimulation of long
lasting immunity. The outcome of this work was then support-
ed by studies carried out by Zaric et al. (129). PGLA NP were
suspended in aqueous blends of 20% w/w PMVE/MA to
fabricate dissolving MN arrays, achieving controlled release
of OVA antigen into the skin layers. This NP/MN delivery
strategy augmented antigen presentation and supported gen-
eration of CD8+ cytotoxic T cell responses and CD4+ Th1
immune responses. This study was significant as it not only
demonstrated successful prophylactic vaccination against both
tumor development and viral challenge, but did so with a
single dosing regimen (129). In terms of specific formulation
considerations, nanoencapsulation was shown in this same
study to improve antigen stability in the MN devices with
potential ramifications for the reduction of cold chain storage
costs. In the latter study, the central role of skin-resident mu-
rine Langerhan’s cells, a sub-set of DCs, in skin immunisation
strategies via this same NP/MN delivery mechanism, were
elucidated (142).
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Moving on from the aforementioned studies, ever more
complicated NP approaches continue to be developed. For
example, Kim et al. have studied polyplex DNA vaccines coat-
ed onto MN arrays through pH responsive polyelectrolyte
multilayer assembly. In brief, solid polycarbonate MN arrays
were used to deliver a range of cargoes with robust humoral
immune responses demonstrated, in comparison to delivery of
the same cargoes via conventional SC injection (143).
Following this, Hu et al. carried out studies to exemplify
MN-assisted dendritic cell targeting of NP for transcutaneous
DNA immunisation in BALB/c mice (144). The MN-assisted
in vivo skin penetration of mannosylated grafted cell-
penetrating peptide-low molecular weight copolymer NPs
was investigated, DC-targeting efficiency was measured and
the induction of protective and therapeutic anti-tumour im-
munity was monitored. In this thorough study, the authors
reported that the process efficiently promoted Trp2-specific
cellular immune responses, resulting in effective protection
against B16 melanoma challenge. The NP formulation
strongly induced CD8+ cytotoxic T cells and CD4+ T cells,
which secreted interferon-gamma and interleukin 12 cyto-
kines, against melanoma cells. This study, along with others,
once again indicates that combinatorial NP/MN strategies
have the potential to provide real immunotherapeutic effects.
It has been well documented that MN technologies can
assist in the delivery of therapeutic agents to the skin.
Therefore, combining this technology with the many positive
aspects of NP formulation, specifically in terms of the potential
for prolonged antigen stability, depot release and the augmen-
tation of immune responses, serve to make this combinatorial
strategy an enticing and exciting area for future research.
Initial formulation strategies featuring antigen laden NPs have
been published and since then, the field of research has ex-
panded to include the incorporation of NP-based therapeutics
into MN devices. Further work on individualized formulation
processes for antigen and DNA vaccine components is abso-
lutely required before a vaccine MN product, incorporating
NPs, will be realised. However a firm base of literature now
exists for future research to build upon and develop.
Other Uses
MNarrays used in combination with NPs andMPs have been
employed in alternative applications, rather than just in drug
and vaccine delivery. Their other main field of use is in the
delivery of metallic NPs for diagnostic purposes but other uses
can also be found in the literature.
Optical coherence tomography (OCT) is a promising di-
agnostic tool for cancer detection in its earlier stages. The
main limitation of this technique however is the low contrast
levels in biological tissue, especially between normal and neo-
plastic tissue. The use of contrast agents such, as gold NPs, can
be used to overcome this limitation. For example, Kim et al.
studied the delivery of gold NPs (71 nm in diameter) across the
SC and the epithelial barriers after treating the skin with aMN
roller device (145). The NP diffusion through the
microchannels created by the MN roller was enhanced by
the use of ultrasound. The system was successfully used in a
model for oral carcinogenesis increasing the contrast level of
the OCT technique by approximately 150%. Furthermore,
the same research group developed a dissolving MN array
containing gold NPs for the same purpose (146). The MN
arrays were formulated from sodium carboxymethyl cellulose
(CMC) and sucrose. Upon application of the arrays to ham-
ster skin, they dissolved releasing the gold NPs. In order to
enhance the permeation of the particles, ultrasound was again
employed. The use of the MN/NP system in the treated tissue
noticeably enhanced the optical contrast if the OCT images.
MN technology can be used for theranostic applications
when combined with QD. Gittard et al. usedMN arrays made
of an acrylate-based polymer to inject QD into porcine skin
(147). The developed system was able to inject the QD into
the deep epidermis and dermis of the skin. Multiphoton mi-
croscopy was then used to track the QD and to visualize the
needles inserted in the tissue. Due to the ability to inject QD
with minimal pain sensation and without injection site trauma
or inflammation, this approach is suitable for further
theranostics applications. The same research group also de-
veloped organically-modified ceramic MNs for the enhanced
delivery of PEG-amine QD solutions into porcine skin (148).
The MN arrays were used to create microchannels in the
biological tissue and subsequently a solution containing QDs
was applied to the treated skin. After the administration of the
QD formulation, the nanometric particles were found in the
deep epidermal and dermal layers of the porcine skin. The use
ofMNs has therefore been shown to be a viable alternative for
QD delivery through the skin. Nevertheless, more studies
should be conducted to provide further evidence for the effec-
tiveness of the QD in theranostic applications after their de-
livery to the deeper layers of the skin.
NPs and MPs have been used to improve the mechanical
properties of MNs. For example, Raja et al. developed silk
protein MN arrays loaded with silk MPs to increase the me-
chanical strength of these needles (149). Additionally, the MPs
were loaded with BSA and with sulforhodamine and the re-
lease of these molecules was evaluated in a 3D collagen gel
and in human cadaver skin, respectively. Following the same
strategy, Yan et al. developed a nanocomposite to prepareMN
arrays (150). The presence of 5% (w/w) of layered double
hydroxides NPs inside CMC MNs resulted in improved me-
chanical properties without compromising the dissolution rate
of the MNs in the skin.
Finally, NPs/MPs can be included inside MN arrays to
trigger drug release under certain conditions. Kim et al. devel-
oped biodegradable PLGA MN with internalised hydrogel
MPs that enhance drug delivery from the needle tips (151).
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Hydrogel MPs (10–40 μm) were made by radical cross-linking
of N-isopropylacrylamide. Once the MN arrays were inserted
into the skin, the particles began to swell and subsequently
enabled the failure of the needles (Fig. 10a). This system can
be used to deliver both hydrophilic and hydrophobic com-
pounds. Some NP variants harbour interesting radiation re-
sponsive properties that have been used to design infrared
triggered drug release MN arrays. Chen et al. developed
polycaprolactone MN arrays containing silica-coated lantha-
num hexaboride nanostructures that acted as a local heat
source when the array was irradiated with near-infrared radi-
ation (152,153). After irradiation the temperature reached
within the arrays was 50°C (152,153), thus inducing a phase
transition on the polycaprolactone, leading to the melting of
the needles (Fig. 10b). This phenomena triggered drug release
from the array. Rhodamine 6G was used as a model molecule
to ascertain this behaviour (152,153). Furthermore, the system
was tested in vivo delivering doxorubicin in a rat model after
near-infrared radiation (153).
CONCLUSIONS
The combination of nanomedicine and MN technology strat-
egies has been made possible due to the exponential growth
and development of new (scientific/manufacturing/fabrica-
tion) technologies over the course of the last decade. This
review has explored and focused on some of the (key) studies
charting the concerted development of nanomedicine and
MN technology, in a bid to provide a coherent and up-to-
date revision of this niche scientific area. The majority of the
research works explored in this review have focused on the
permeation of NP or on the release of modelmolecules such as
dyes. The main aim of these papers is to demonstrate the
feasibility of this technology to deliver NP into the viable skin.
Special attention was also paid to the emerging field of
protein/DNA based vaccine delivery from NP/MN plat-
forms. As with so many aspects of science and technological
developments, it is abundantly clear that although the realm
of nanomedicine and MN technologies holds tremendous
promise, further research is required in order to fully under-
stand and then exploit its inherent capabilities.
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